Scorr-Insert
X

Find Approved Endocrinology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sildenafil Citrate

            Therapeutic Area: Endocrinology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2020

            Details:

            FDA supported Aspargo’s plan to conduct a single dose bioequivalent study to assess the pharmacokinetics, bioequivalency, tolerability and safety of the Company’s Sildenafil Oral Spray drug candidate.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Osilodrostat

            Therapeutic Area: Endocrinology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 26, 2020

            Details:

            In the Phase 3 LINC?3 study, a significantly higher proportion of patients treated with Isturisa® (osilodrostat) maintained normal mean urinary free cortisol (mUFC) at the end of the 8?week.

            Ro

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sildenafil Citrate

            Therapeutic Area: Endocrinology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Greenstone LLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 23, 2020

            Details:

            Agreement provides Roman members with erectile dysfunction treatment backed by Pfizer’s quality manufacturing standards and supply chain excellence.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Denosumab,0

            Therapeutic Area: Endocrinology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: $2,800.0 million Upfront Cash: $2,800.0 million

            Deal Type: Collaboration January 02, 2020

            Details:

            The stratagic collaboration between Amgen and BeiGene will significantly accelerate Amgen's plans to expand its oncology presence in China.